| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
|
US6004297 (Pediatric) | NOVO NORDISK INC | Injection syringe |
Jul, 2019
(4 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
|
USRE41956 (Pediatric) | NOVO NORDISK INC | Dose setting limiter |
Jul, 2021
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(19 days from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Novolog Flexpen is owned by Novo Nordisk Inc.
Novolog Flexpen contains Insulin Aspart Recombinant.
Novolog Flexpen has a total of 12 drug patents out of which 10 drug patents have expired.
Expired drug patents of Novolog Flexpen are:
- US5618913
- US5618913*PED
- US5866538
- US5866538*PED
- USRE43834
- US6004297
- US6004297*PED
- USRE41956
- USRE41956*PED
- US8579869
Novolog Flexpen was authorised for market use on 31 October, 2013.
Novolog Flexpen is available in injectable;subcutaneous dosage forms.
The generics of Novolog Flexpen are possible to be released after 23 September, 2032.
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXPEN family patents
